Abstract
Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of IgE. Omalizumab has been approved for the treatment of moderate to severe asthma; however, there is currently more and more data showing promising results in the management also of chronic urticaria. We present a case series of 19 patients with chronic urticaria treated in a university department with omalizumab and give an overview of the existing literature comprising an additional 59 cases as well as a total of 139 patients enrolled in two randomized controlled trials comparing omalizumab with placebo. The collective evidence points to omalizumab as a safe and effective treatment option for patients with chronic urticaria who do not sufficiently respond to standard therapy as recommended by existing guidelines.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Case Reports in Dermatology |
| Vol/bind | 4 |
| Udgave nummer | 1 |
| Sider (fra-til) | 19-26 |
| Antal sider | 8 |
| ISSN | 1662-6567 |
| DOI | |
| Status | Udgivet - 2012 |